Heron Therapeutics Inc (OQ:HRTX)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4242 Campus Point Ct Ste 200
SAN DIEGO CA 92121
Tel: N/A
Website: www.herontx.com
IR: See website
<
Key People
Kevin C. Tang
Independent Chairman of the Board
Barry D. Quart
President, Chief Executive Officer, Director
Robert E. Hoffman
Chief Financial Officer, Senior Vice President - Finance
Kimberly J. Manhard
Executive Vice President - Drug Development
David L. Szekeres
Senior Vice President, General Counsel, Business Development, Corporate Secretary
Thomas B. Ottoboni
Senior Vice President - Pharmaceutical and Preclinical Research and Development
Sean T. Ristine
Vice President - Human Resources
   
Business Overview
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
Financial Overview
For the three months ended 31 March 2019, Heron Therapeutics Inc revenues increased from $11.6M to $31.6M. Net loss increased 21% to $63M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 73% to $19.8M (expense), Stock-based Compensation in SGA increase from $2.4M to $8.9M (expense).
Employees: 198 as of Feb 1, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,126M as of Mar 31, 2019
Annual revenue (TTM): $97.51M as of Mar 31, 2019
EBITDA (TTM): -$195.05M as of Mar 31, 2019
Net annual income (TTM): -$189.59M as of Mar 31, 2019
Free cash flow (TTM): -$189.52M as of Mar 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 79,194,227 as of Apr 22, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization